CGTxchange pairs an AI-enabled evaluation platform with ASGCT's global network to connect deprioritized rare disease programs with new sponsors and investors.
People with erythropoietic protoporphyria (EPP) must go to great lengths to avoid sun exposure. There have been no approved treatments that address the disease mechanism, but a new drug could change that.
Forty years after the Orphan Drug Act passed, researchers advance drug development for neglected rare conditions everywhere from the lab bench to backstage.